December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Randomised Trial Comparing Brimonidine and Timolol in the Initial Management of Acute Angle Closure
Author Affiliations & Notes
  • Y Liu
    Clinical Trials & Epidemiology Research Unit Singapore Singapore
  • T Aung
    Singapore National Eye Centre Singapore Singapore
  • FT S Oen
    Singapore National Eye Centre Singapore Singapore
  • B-K Khoo
    Tan Tock Seng Hospital Singapore Singapore
  • Y-H Chan
    Clinical Trials & Epidemiology Research Unit Singapore Singapore
  • C-L Ho
    Singapore National Eye Centre Singapore Singapore
  • LH Thean
    National University Hospital Singapore Singapore
  • SK L Seah
    Singapore National Eye Centre Singapore Singapore
  • PT K Chew
    National University of Singapore Singapore Singapore
  • Footnotes
    Commercial Relationships   Y. Liu, None; T. Aung, None; F.T.S. Oen, None; B. Khoo, None; Y. Chan, None; C. Ho, None; L.H. Thean, None; S.K.L. Seah, None; P.T.K. Chew, Allergan F. Grant Identification: Unrestricited grant from Allergan
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 3421. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y Liu, T Aung, FT S Oen, B-K Khoo, Y-H Chan, C-L Ho, LH Thean, SK L Seah, PT K Chew; Randomised Trial Comparing Brimonidine and Timolol in the Initial Management of Acute Angle Closure . Invest. Ophthalmol. Vis. Sci. 2002;43(13):3421.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To compare the effect of brimonidine and timolol in the initial management of acute angle closure (AAC). Methods: One hundred and seven patients with AAC at 3 Singapore hospitals were recruited into the study. In addition to receiving systemic acetazolamide, topical pilocarpine and steroids, patients were randomised to treatment with either brimonidine 0.2% or timolol 0.5% at presentation and twice daily thereafter. The main outcome measures were the resolution of the acute attack and the need for filtering surgery due to failed medical treatment. Patients were further analyzed for factors that may have contributed to failure of resolution of the acute episode using logistic regression, taking into account demographic factors, past medical history and factors related to the acute glaucoma episode. Results: Of the 107 subjects, there were 83 females (77.6%), and the majority of subjects (95%) were Chinese. The mean age was 61.6 9.1 years (range 42.6 to 83.6). 48 subjects were randomised to brimonidine treatment and 59 to timolol. The mean duration of acute symptoms was 2.3 + 2.7 days in the brimonidine-treated group and 2.5 + 2.7 days in the timolol-treated group. There was failure of resolution of the acute attack in 3/48 subjects (6.3%, 95% CI 1.3% to 17.2%) in the brimonidine-treated group, as compared to 10/59 subjects (17%, 95% CI 8.4% to 29%) in the timolol-treated group (p = 0.09, OR = 3.1 [95% CI 0.79 to 11.8]). Adjusting for age, sex, duration of symptoms and history of ischemic risk factors (diabetes, hypertension or ischemic heart disease), the odds ratio increased to 4.0 (95% CI 0.94 to 16.7, p = 0.06). Filtering surgery due to failed medical treatment was required for 3/48 subjects and 5/59 subjects (8.5%, 95% CI 2.8% to 18.7%) respectively (p=0.73). Conclusion: In the initial management of acute angle closure, patients treated with timolol seem to have a higher risk of failure of resolution of the acute attack as compared to those treated with brimonidine, although the rates of filtering surgery required due to failed medical treatment were comparable in the 2 groups.

Keywords: 353 clinical (human) or epidemiologic studies: outcomes/complications 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×